Cargando…
The Profile of Autoimmunity in Type 1 Diabetes Patients
BACKGROUND: Type 1 diabetes mellitus (T1DM) is an autoimmune disorder caused by pancreatic β-cells destruction. Anti-pancreatic antibodies are the witness of β-cell destruction and their dosage is mainly used for etiological diagnosis. Patients with T1DM are at increased risk of developing other aut...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102891/ https://www.ncbi.nlm.nih.gov/pubmed/33727507 http://dx.doi.org/10.4103/aam.aam_8_20 |
_version_ | 1783689199135752192 |
---|---|
author | Derrou, Sara El Guendouz, Fayçal Benabdelfedil, Yousra Chakri, Imad Ouleghzal, Hassan Safi, Somaya |
author_facet | Derrou, Sara El Guendouz, Fayçal Benabdelfedil, Yousra Chakri, Imad Ouleghzal, Hassan Safi, Somaya |
author_sort | Derrou, Sara |
collection | PubMed |
description | BACKGROUND: Type 1 diabetes mellitus (T1DM) is an autoimmune disorder caused by pancreatic β-cells destruction. Anti-pancreatic antibodies are the witness of β-cell destruction and their dosage is mainly used for etiological diagnosis. Patients with T1DM are at increased risk of developing other autoimmune reactions, which may involve other organs, resulting in organ specific autoimmune disease. The most frequently encountered are autoimmune thyroid disease, followed by celiac and gastric disease and other rare autoimmune diseases. OBJECTIVES: The purpose of this study is to investigate the prevalence of autoimmune markers in patients with T1DM. METHODS: The study was conducted at the Department of Endocrinology of the Military Hospital Moulay Ismail in Meknes Morocco, from January 2016 to December 2018. All Type 1 diabetes patients consulting during the study period were included in the study. Their clinical and biochemical data were collected at their first presentation, made up of anti-pancreatic antibodies (glutamic acid decarboxylase [GAD] antibody, tyrosine phosphatase antibody, and islet cell antibody) and other organ-specific antibodies: the thyroid (antithyroid peroxidase antibody, antithyroglobulin antibody, and antithyroid-stimulating hormone receptor antibody), the intestine (IgA antitissue transglutaminase antibody), the adrenal gland (anti-21 hydroxylase antibody), and the stomach (antigastric parietal cell antibody and anti-intrinsic factor antibody). RESULTS: Fifty-four patients were included, with an average age of 26 years. GAD, tyrosine phosphatase, and islet cell antibodies were detected in 74%, 22%, and 3.7%, respectively, of the 54 patients examined. The prevalence of extrapancreatic autoimmunity was 45% with a large preponderance among different immunities of those from thyroid and celiac diseases (CDs). CONCLUSION: Our results confirm that patients with Type 1 diabetes should be investigated for the presence of autoimmune diseases mainly from thyroid and CDs. |
format | Online Article Text |
id | pubmed-8102891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-81028912021-06-02 The Profile of Autoimmunity in Type 1 Diabetes Patients Derrou, Sara El Guendouz, Fayçal Benabdelfedil, Yousra Chakri, Imad Ouleghzal, Hassan Safi, Somaya Ann Afr Med Original Article BACKGROUND: Type 1 diabetes mellitus (T1DM) is an autoimmune disorder caused by pancreatic β-cells destruction. Anti-pancreatic antibodies are the witness of β-cell destruction and their dosage is mainly used for etiological diagnosis. Patients with T1DM are at increased risk of developing other autoimmune reactions, which may involve other organs, resulting in organ specific autoimmune disease. The most frequently encountered are autoimmune thyroid disease, followed by celiac and gastric disease and other rare autoimmune diseases. OBJECTIVES: The purpose of this study is to investigate the prevalence of autoimmune markers in patients with T1DM. METHODS: The study was conducted at the Department of Endocrinology of the Military Hospital Moulay Ismail in Meknes Morocco, from January 2016 to December 2018. All Type 1 diabetes patients consulting during the study period were included in the study. Their clinical and biochemical data were collected at their first presentation, made up of anti-pancreatic antibodies (glutamic acid decarboxylase [GAD] antibody, tyrosine phosphatase antibody, and islet cell antibody) and other organ-specific antibodies: the thyroid (antithyroid peroxidase antibody, antithyroglobulin antibody, and antithyroid-stimulating hormone receptor antibody), the intestine (IgA antitissue transglutaminase antibody), the adrenal gland (anti-21 hydroxylase antibody), and the stomach (antigastric parietal cell antibody and anti-intrinsic factor antibody). RESULTS: Fifty-four patients were included, with an average age of 26 years. GAD, tyrosine phosphatase, and islet cell antibodies were detected in 74%, 22%, and 3.7%, respectively, of the 54 patients examined. The prevalence of extrapancreatic autoimmunity was 45% with a large preponderance among different immunities of those from thyroid and celiac diseases (CDs). CONCLUSION: Our results confirm that patients with Type 1 diabetes should be investigated for the presence of autoimmune diseases mainly from thyroid and CDs. Wolters Kluwer - Medknow 2021 2021-03-13 /pmc/articles/PMC8102891/ /pubmed/33727507 http://dx.doi.org/10.4103/aam.aam_8_20 Text en Copyright: © 2021 Annals of African Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Derrou, Sara El Guendouz, Fayçal Benabdelfedil, Yousra Chakri, Imad Ouleghzal, Hassan Safi, Somaya The Profile of Autoimmunity in Type 1 Diabetes Patients |
title | The Profile of Autoimmunity in Type 1 Diabetes Patients |
title_full | The Profile of Autoimmunity in Type 1 Diabetes Patients |
title_fullStr | The Profile of Autoimmunity in Type 1 Diabetes Patients |
title_full_unstemmed | The Profile of Autoimmunity in Type 1 Diabetes Patients |
title_short | The Profile of Autoimmunity in Type 1 Diabetes Patients |
title_sort | profile of autoimmunity in type 1 diabetes patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102891/ https://www.ncbi.nlm.nih.gov/pubmed/33727507 http://dx.doi.org/10.4103/aam.aam_8_20 |
work_keys_str_mv | AT derrousara theprofileofautoimmunityintype1diabetespatients AT elguendouzfaycal theprofileofautoimmunityintype1diabetespatients AT benabdelfedilyousra theprofileofautoimmunityintype1diabetespatients AT chakriimad theprofileofautoimmunityintype1diabetespatients AT ouleghzalhassan theprofileofautoimmunityintype1diabetespatients AT safisomaya theprofileofautoimmunityintype1diabetespatients AT derrousara profileofautoimmunityintype1diabetespatients AT elguendouzfaycal profileofautoimmunityintype1diabetespatients AT benabdelfedilyousra profileofautoimmunityintype1diabetespatients AT chakriimad profileofautoimmunityintype1diabetespatients AT ouleghzalhassan profileofautoimmunityintype1diabetespatients AT safisomaya profileofautoimmunityintype1diabetespatients |